Drug Profile
MGI 197
Latest Information Update: 08 Dec 1998
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer MGI Pharma; Nonindustrial source
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic retinopathy
Most Recent Events
- 08 Dec 1998 Discontinued-Preclinical for Diabetic retinopathy in USA (Unknown route)
- 04 Sep 1996 Suspended-Preclinical for Diabetic retinopathy in USA (Unknown route)
- 29 Aug 1996 New profile